Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Mansour Alfayez, Hagop Kantarjian, Tapan Kadia, Farhad Ravandi-Kashani & Naval Daver. (2020) CPX-351 (vyxeos) in AML. Leukemia & Lymphoma 61:2, pages 288-297.
Read now
Read now
Li Zhou, Xin Liu, Huilan Liu, Weibo Zhu, Xiaoyan Cai, Kaidi Song, Changcheng Zheng, Baolin Tang & Zimin Sun. (2016) A comparative study of idarubicin 12 mg/m2 and 8 mg/m2 combined with cytarabine as the first induction regimen for adult acute myeloid leukemia patients. OncoTargets and Therapy 9, pages 985-991.
Read now
Read now
Gertjan JL Kaspers. (2012) Pediatric acute myeloid leukemia. Expert Review of Anticancer Therapy 12:3, pages 405-413.
Read now
Read now
Roberto Stasi. (2008) Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia. Expert Opinion on Biological Therapy 8:4, pages 527-540.
Read now
Read now
Karen Seiter, Delong Liu, Eric Feldman, Qiuhu Shi, Anila Qureshi, Muhammad Arshad, Tamana Walia, Nauman Naseer, Paul Baskind & Tauseef Ahmed. (2006) Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Twelve year results from a single institution. Leukemia & Lymphoma 47:3, pages 425-432.
Read now
Read now
Peter Cassileth, Sandra Lee, Mark Litzow, Kenneth Miller, Edward Stadtmauer, Martin Tallman, Hillard Lazarus, John Bennett, Elisabeth Paietta, Gordon Dewald & Jacob Rowe. (2005) Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an eastern cooperative oncology group trial (E4995). Leukemia & Lymphoma 46:1, pages 55-61.
Read now
Read now
AP Grigg, J Reynolds, A McQuillan, SK Juneja, J Di Iulio, C Hui, C Smith, R Kimber, KF Bradstock & on behalf of the Australasian Leukaemia and Lymphoma Group. (2005) Prognostic features for response and survival in elderly patients with de novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine. Leukemia & Lymphoma 46:3, pages 367-375.
Read now
Read now
Luisa Mantovani, Dirk Hasenclever, Rainer Krahl, Wolfram Pönisch, Michael Herold, Rita Pasold, Friedrich Fiedler, Gottfried Dölken, Dietrich Kämpfe, Hans Joachim Schmoll, Rita Súbert, Martin Kubel, Dietger Niederwieser & Werner Helbig. (2002) Intermediate-dose Cytarabine Treatment Delivered at Moderate Infusion Rates for De Novo Acute Myeloid Leukemia-Results of a phase I-II Study. Leukemia & Lymphoma 43:2, pages 265-274.
Read now
Read now
E. Jourdan, J. Reiffers, A. M. Stoppa, J. J. Sotto, M. Attal, R. Bouabdallaha, G Marit, N. Fégueux, O. Boulat, N. Dastugue, J. M. Boiron, C. Fabères, J. A. Gastaut, D. Maraninchi & D. Blaise. (2001) Outcome of Adult Patients with Acute Myeloid Leukemia who Failed to Achieve Complete Remission after one Course of Induction Chemotherapy: A Report from the BGMT Study Group: For the BGMT. Leukemia & Lymphoma 42:1-2, pages 57-65.
Read now
Read now
Rm Lowenthal, Kf Bradstock, Jp Matthews, Jf Bishop, S. Juneja, R. Cobcroft, P. Eliadis, A. Enno, D. Gill, Rp Herrmann, A. Manoharan, Fj Page, Kf Rooney, D. Roseneld, M. Seldon, Km Taylor, Mm Wolf & Gar Young. (1999) A Phase I/II Study of Intensive Dose Escalation of Cytarabine in Combination with Idarubicin and Etoposide in Induction and Consolidation Treatment of Adult Acute Myeloid Leukemia. Leukemia & Lymphoma 34:5-6, pages 501-510.
Read now
Read now
Articles from other publishers (35)
Sandra S. Rohr, Raul C. Maranhão, Thauany M. Tavoni, Aleksandra T. Morikawa, Kelsy Areco, Debora F. Deus & José S.R. Oliveira. (2020) Novel Approach for Bone Marrow Transplantation Conditioning in Acute Myelogenous Leukemia not Responding to the Induction Therapy Using Etoposide Carried in Lipid Core Nanoparticles: A Pilot Clinical Study. Biology of Blood and Marrow Transplantation 26:11, pages 2027-2033.
Crossref
Crossref
Melhem M Solh, Scott R. Solomon, Lawrence E. Morris, Xu Zhang, H. Kent Holland & Asad Bashey. (2020) Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine). Leukemia Research 93, pages 106318.
Crossref
Crossref
Martin S. TallmanEunice S. WangJessica K. AltmanFrederick R. AppelbaumVijaya Raj BhattDale BixbySteven E. CoutreMarcos De LimaAmir T. FathiMelanie FiorellaJames M. ForanAric C. HallMeagan JacobyJeffrey LancetThomas W. LeBlancGabriel MannisGuido MarcucciMichael G. MartinAlice MimsMargaret R. O’DonnellRebecca OlinDeniz PekerAlexander PerlDaniel A. PollyeaKeith PratzThomas PrebetFarhad RavandiPaul J. ShamiRichard M. StoneStephen A. Strickland, Matthew WieduwiltKristina M. Gregory, Lydia Hammond & Ndiya Ogba. (2019) Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 17:6, pages 721-749.
Crossref
Crossref
Meng Su, Yu‐Ting Chang, Daniela Hernandez, Richard J. Jones & Gabriel Ghiaur. (2019) Regulation of drug metabolizing enzymes in the leukaemic bone marrow microenvironment. Journal of Cellular and Molecular Medicine 23:6, pages 4111-4117.
Crossref
Crossref
Jingsong He, Li Li, Jingjing Zhu, Weiyan Zheng, Wenjun Wu, Yanlong Zheng & Xiujin Ye. (2017) Novel homobarringtonie‑containing therapy for the treatment of patients with primary acute myeloid leukemia that are resistant to conventional therapy. Oncology Letters.
Crossref
Crossref
Jae-Ho YoonHee-Je KimDae-Hun KwakGi June MinSung-Soo ParkYoung-Woo JeonSung-Eun LeeByung-Sik ChoKi-Seong EomYoo-Jin KimSeok LeeChang-Ki MinSeok-Goo ChoDong-Wook KimJong Wook LeeWoo-Sung Min. (2017) Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia. Blood Research 52:3, pages 174.
Crossref
Crossref
J Magenau, P Westervelt, S Khaled, J McGuirk, P Hari, M Eapen, P S Becker, B Parkin, T Braun, B Logan, H Wang, M Jagasia, S D Rowley, D D H Kim, T Schechter, N Frey, B Scott, T Churay, S Lieland, S Forman & S Mineishi. (2016) A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation 52:1, pages 59-65.
Crossref
Crossref
Marlise R. LuskinJu-Whei LeeHugo F. FernandezOmar Abdel-WahabJohn M. BennettRhett P. KetterlingHillard M. LazarusRoss L. LevineMark R. LitzowElisabeth M. Paietta, Jay P. Patel, Janis Racevskis, Jacob M. Rowe, Martin S. TallmanZhuoxin SunSelina M. Luger. (2016) Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood 127:12, pages 1551-1558.
Crossref
Crossref
Brygida Bisikirska, Mukesh Bansal, Yao Shen, Julie Teruya-Feldstein, Raju Chaganti & Andrea Califano. (2016) Elucidation and Pharmacological Targeting of Novel Molecular Drivers of Follicular Lymphoma Progression. Cancer Research 76:3, pages 664-674.
Crossref
Crossref
Øystein Bruserud, Håkon Reikvam, Astrid Olsnes Kittang, Aymen Bushra Ahmed, Tor Henrik Anderson Tvedt, Malvin Sjo & Kimberley Joanne Hatfield. (2012) High-dose etoposide in allogeneic stem cell transplantation. Cancer Chemotherapy and Pharmacology 70:6, pages 765-782.
Crossref
Crossref
Arati V. Rao, David A. Rizzieri, Carlos M. DeCastro, Louis F. Diehl, Anand S. Lagoo, Joseph O. Moore & Jon P. Gockerman. (2012) Phase I study of dose dense induction and consolidation with gemtuzumab ozogamicin and high dose cytarabine in older adults with AML. Journal of Geriatric Oncology 3:3, pages 220-227.
Crossref
Crossref
Martin S. Tallman, Ritesh Parajuli & Jessica K. Altman. 2011. Advances in Malignant Hematology. Advances in Malignant Hematology
103
126
.
Brenda Gibson, John Perentesis, Todd A. Alonzo & Gertjan J. L. Kaspers. 2011. Childhood Leukemia. Childhood Leukemia
121
160
.
Hagop Kantarjian, Farhad Ravandi, Susan O'Brien, Jorge Cortes, Stefan Faderl, Guillermo Garcia-Manero, Elias Jabbour, William Wierda, Tapan Kadia, Sherry Pierce, Jianqin Shan, Michael Keating & Emil J. Freireich. (2010) Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116:22, pages 4422-4429.
Crossref
Crossref
Franco MandelliMarco VignettiStefan SuciuRoberto StasiMaria-Concetta PettiGiovanna MeloniPetra MuusFilippo MarmontJean-Pierre MarieBoris LabarXavier ThomasFrancesco Di RaimondoRoel WillemzeVincenzo LisoFelicetto FerraraLiliana BailaPaola FaziRobert ZittounSergio AmadoriTheo de Witte. (2009) Daunorubicin Versus Mitoxantrone Versus Idarubicin As Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10. Journal of Clinical Oncology 27:32, pages 5397-5403.
Crossref
Crossref
Hugo F. Fernandez, Zhuoxin Sun, Xiaopan Yao, Mark R. Litzow, Selina M. Luger, Elisabeth M. Paietta, Janis Racevskis, Gordon W. Dewald, Rhett P. Ketterling, John M. Bennett, Jacob M. Rowe, Hillard M. Lazarus & Martin S. Tallman. (2009) Anthracycline Dose Intensification in Acute Myeloid Leukemia. New England Journal of Medicine 361:13, pages 1249-1259.
Crossref
Crossref
Jiazhuo Liu, Yingchang Mi, Mingwei Fu, Wenjuan Yu, Ying Wang, Dong Lin, Shougeng Bian & Jianxiang Wang. (2009) Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia. American Journal of Hematology 84:7, pages 422-427.
Crossref
Crossref
Stephen H. Petersdorf, Cathryn Rankin, David R. Head, Howard R. Terebelo, Cheryl L. Willman, Stanley P. Balcerzak, Anand B. Karnad, Shaker R. Dakhil & Frederick R. Appelbaum. (2007) Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG‐9500). American Journal of Hematology 82:12, pages 1056-1062.
Crossref
Crossref
John G. Gribben. 2005. The Cancer Handbook. The Cancer Handbook.
Richard M. Stone. 2007. Acute Myelogenous Leukemia. Acute Myelogenous Leukemia
373
384
.
Jonathan E. Kolitz. (2006) Current therapeutic strategies for acute myeloid leukaemia. British Journal of Haematology 134:6, pages 555-572.
Crossref
Crossref
Elihu H. Estey. (2006) General Approach to, and Perspectives on Clinical Research in, Older Patients With Newly Diagnosed Acute Myeloid Leukemia. Seminars in Hematology 43:2, pages 89-95.
Crossref
Crossref
Hagop Kantarjian, Susan O'Brien, Jorge Cortes, Francis Giles, Stefan Faderl, Elias Jabbour, Guillermo Garcia-Manero, William Wierda, Sherry Pierce, Jianqin Shan & Elihu Estey. (2006) Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome:. Cancer 106:5, pages 1090-1098.
Crossref
Crossref
Elias J. Jabbour, Elihu Estey & Hagop M. Kantarjian. (2006) Adult Acute Myeloid Leukemia. Mayo Clinic Proceedings 81:2, pages 247-260.
Crossref
Crossref
Anne-Marie Stoppa, Norbert Vey, Reda Bouabdallah, Catherine Faucher, Régis Costello, Diane Coso, Danielle Sainty, Christine Arnoulet, Marina Lafage, Marie-Joelle Mozziconacci, Didier Blaise, Jean-Albert Gastaut & Dominique Maraninchi. (2006) Pronostic et traitement des leucémies aiguës myéloblastiques. EMC - Hématologie 1:1, pages 1-13.
Crossref
Crossref
Gunnar Juliusson, Martin Höglund, Karin Karlsson, Christina Löfgren, Lars Möllgård, Christer Paul, Ulf Tidefelt & Magnus Björkholm. (2003) Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study. British Journal of Haematology 123:5, pages 810-818.
Crossref
Crossref
Yaddanapudi Ravindranath. (2003) Recent advances in pediatric acute lymphoblastic and myeloid leukemia. Current Opinion in Oncology 15:1, pages 23-35.
Crossref
Crossref
J. P. Matthews, J. F. Bishop, G. A. R. Young, S. K. Juneja, R. M. Lowenthal, O. M. Garson, R. G. Cobcroft, A. J. Dodds, A. Enno, E. A. Gillett, R. P. Hermann, D. E. Joshua, D. D. Ma, J. Szer, K. M. Taylor, M. Wolf & K. F. Bradstock. (2001) Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia. British Journal of Haematology 113:3, pages 727-736.
Crossref
Crossref
K Seiter, EJ Feldman, C Sreekantaiah, M Pozzuoli, J Weisberger, D Liu, C Papageorgio, M Weiss, R Kancherla & T Ahmed. (2001) Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy. Leukemia 15:6, pages 963-970.
Crossref
Crossref
Martin S. Tallman. (2017) Therapy of Acute Myeloid Leukemia. Cancer Control 8:1, pages 62-78.
Crossref
Crossref
AS Stein, MR O'Donnell, ML Slovak, A Nademanee, A Dagis, GM Schmidt, PM Parker, DS Snyder, EP Smith, G Somlo, KA Margolin, D Arber, J Niland & SJ Forman. (2000) High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission. Leukemia 14:7, pages 1191-1196.
Crossref
Crossref
Martin S. Tallman. (2000) Double induction with high-dose cytarabine is a safe and effective strategy for delivering early intensification treatment for AML. Evidence-based Oncology 1:1, pages 18-19.
Crossref
Crossref
Larry D. Cripe & Stuart Hinton. (2000) Acute myeloid leukemia in adults. Current Treatment Options in Oncology 1:1, pages 9-17.
Crossref
Crossref
Michael Flasshove, Werner Frings, Jan K Schröder, Thomas Moritz, Jochen Schütte & Siegfried Seeber. (1999) Transfer of the cytidine deaminase cDNA into hematopoietic cells. Leukemia Research 23:11, pages 1047-1053.
Crossref
Crossref
A. H. STRICKLAND, C. SEYMOUR, H. M. PRINCE, M. WOLF, S. JUNEJA & E. H. JANUSZEWICZ. (2008) Fludarabine and high dose cytarabine (FLA): a well tolerated salvage regimen in acute myeloid leukaemia. Australian and New Zealand Journal of Medicine 29:4, pages 556-558.
Crossref
Crossref